Cargando…
Long term survival of small cell lung cancer patients after chemotherapy.
Eighty-one patients with small cell lung cancer (SCLC) with a survival of more than 2 years after start of chemotherapy were studied. Twenty-six of the 28 patients who died of relapsed SCLC had in fact relapsed before two years and of the 55 who had not then only two (4%) relapsed subsequently. It i...
Autores principales: | van der Gaast, A., Postmus, P. E., Burghouts, J., van Bolhuis, C., Stam, J., Splinter, T. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968359/ https://www.ncbi.nlm.nih.gov/pubmed/8385981 |
Ejemplares similares
-
Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.
por: van der Gaast, A., et al.
Publicado: (1991) -
Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
por: van der Gaast, A., et al.
Publicado: (1994) -
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy
por: Polee, M B, et al.
Publicado: (2003) -
Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase.
por: Splinter, T. A., et al.
Publicado: (1992) -
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer
por: Gaast, A van der, et al.
Publicado: (1999)